Radiopharm Theranostics (RDPTF) Profit After Tax Growth (3y) (2026)
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Profit After Tax Growth (3y) (2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.13 Bn | 198.14 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 181.95 Bn | 178.77 Bn | 6.22 Bn | -129.22% |
| 3 | Vertex Pharmaceuticals | 132.50 Bn | 124.65 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.67 Bn | 74.68 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.23 Bn | 30.92 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.46 Bn | 30.18 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.19 Bn | 30.19 Bn | 1.16 Mn | - |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 | 72.80% |